Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia
CONCLUSION: EcA variants demonstrated better pharmacological properties compared to WT that makes them good candidates for further development.PMID:38412663 | DOI:10.1016/j.tranon.2024.101909
Source: Translational Oncology - Category: Cancer & Oncology Authors: Soumika Sengupta Mainak Biswas Khushboo A Gandhi Saurabh Kumar Gupta Poonam B Gera Vikram Gota Avinash Sonawane Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Chemotherapy | Gastroenteritis | Leukemia | Study | Toxicology